Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DARLENE M BARTILUCCI

Allopathic & Osteopathic Physicians Family Medicine

NPI
1639156276
CMS profile
118945
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,791.25

116 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,344.10 112
Travel and Lodging $1,438.80 3
Education $8.35 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DARLENE M BARTILUCCI

NPI 1639156276 · CMS profile ID 118945

Allopathic & Osteopathic Physicians / Family Medicine

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639156276?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DARLENE M BARTILUCCI, NPI 1639156276, CMS profile ID 118945. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639156276?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DARLENE M BARTILUCCI, NPI 1639156276, CMS profile ID 118945. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639156276?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DARLENE M BARTILUCCI, NPI 1639156276, CMS profile ID 118945, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639156276?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

116 matching records · $3,791.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 116 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 116.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $13.6006/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681886719 CMS
AstraZeneca Pharmaceuticals LP $14.7706/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685274741 CMS
AstraZeneca Pharmaceuticals LP $11.8406/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685723375 CMS
Kowa Pharmaceuticals America, Inc. $12.5806/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630255245 CMS
Teva Pharmaceuticals USA, Inc. $15.0005/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697771849 CMS
Novo Nordisk Inc $13.7805/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669581027 CMS
Novartis Pharmaceuticals Corporation $13.6905/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658893391 CMS
GlaxoSmithKline, LLC. $14.0505/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670215837 CMS
SANOFI-AVENTIS U.S. LLC $18.0105/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694047779 CMS
Janssen Pharmaceuticals, Inc $13.1105/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658300937 CMS
PFIZER INC. $13.2805/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672178036 CMS
PFIZER INC. $0.8305/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672440750 CMS
Lilly USA, LLC $0.7205/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657764543 CMS
Lilly USA, LLC $10.0605/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657778413 CMS
Merck Sharp & Dohme Corporation $10.8905/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695478037 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.5305/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684642725 CMS
Lilly USA, LLC $10.3405/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657767935 CMS
Lilly USA, LLC $13.3304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657767937 CMS
Novartis Pharmaceuticals Corporation $14.1804/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658893403 CMS
PFIZER INC. $4.4304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672405493 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $101.4304/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700159133 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.1904/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700159127 CMS
PFIZER INC. $12.7204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672248137 CMS
SANOFI-AVENTIS U.S. LLC $82.9704/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693989699 CMS
Astellas Pharma US Inc $18.4904/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655459813 CMS
Allergan Inc. $14.9704/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670088941 CMS
SANOFI-AVENTIS U.S. LLC $12.9704/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693988129 CMS
Merck Sharp & Dohme Corporation $10.8903/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695418035 CMS
Amgen Inc. $17.3703/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662277083 CMS
Novo Nordisk Inc $15.1403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669485295 CMS
Novo Nordisk Inc $1.1403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682634827 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.4903/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682067747 CMS
Kowa Pharmaceuticals America, Inc. $13.1403/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630255243 CMS
Janssen Pharmaceuticals, Inc $13.9603/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658300933 CMS
AstraZeneca Pharmaceuticals LP $13.6003/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685357039 CMS
GlaxoSmithKline, LLC. $12.4403/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670734153 CMS
PFIZER INC. $9.1503/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672419579 CMS
Novo Nordisk Inc $14.2502/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668730235 CMS
Novartis Pharmaceuticals Corporation $13.4902/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658893393 CMS
Amgen Inc. $18.0602/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662277081 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.1102/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709123031 CMS
SANOFI-AVENTIS U.S. LLC $16.3402/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693918455 CMS
Amarin Pharma Inc. $17.8302/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699079233 CMS
AstraZeneca Pharmaceuticals LP $14.3102/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685021281 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.8902/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700159129 CMS
Novo Nordisk Inc $2.4202/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682634821 CMS
PFIZER INC. $12.7202/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672239953 CMS
Novo Nordisk AS $244.6902/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542333 CMS
Novo Nordisk AS $467.5202/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542337 CMS
Novo Nordisk AS $726.5902/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542341 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,791.25 116
PY2020 $1,706.49 103
PY2021 $721.61 44
PY2022 $1,039.49 65
PY2023 $1,694.58 81
PY2024 $1,318.32 63
PY2025 $2,613.02 68

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,445,499.31 243
PY2024 Recipient $1,858.23 11
PY2024 Principal investigator $766,936.25 347
PY2023 Principal investigator $479,665.52 895
PY2022 Principal investigator $17,715.69 367
PY2021 Principal investigator $14,720.37 256
PY2020 Principal investigator $71,061.51 71
PY2019 Principal investigator $263,827.82 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

243 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,612.00 12/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $138.24 12/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,586.25 12/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,490.75 12/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279156
Principal investigator 1 ABBVIE INC. $518.94 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $457.14 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,400.00 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,652.50 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,489.50 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $729.00 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,227.50 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.20 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.90 12/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269371
Principal investigator 1 ABBVIE INC. $850.00 11/26/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202525490
Principal investigator 1 ABBVIE INC. $1,392.15 11/20/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202524826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,898.21 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $358.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,485.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.20 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.72 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $450.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,755.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.68 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,755.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $525.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.84 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.20 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $450.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95.76 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.92 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,755.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.80 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64,685.25 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.00 11/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,999.26 11/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259133
Principal investigator 1 ABBVIE INC. $197.98 11/06/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202523263
Principal investigator 1 ABBVIE INC. $670.96 11/05/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521871
Principal investigator 1 ABBVIE INC. $62,521.04 11/05/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522029
Principal investigator 1 ABBVIE INC. $764.90 11/05/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,528.98 10/29/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,550.32 10/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 10/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.86 10/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252668
Principal investigator 1 ABBVIE INC. $447.98 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202517243
Principal investigator 1 ABBVIE INC. $75.00 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202517245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,905.34 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $117.41 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250783
Principal investigator 1 ABBVIE INC. $247.98 10/15/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516961
Principal investigator 1 ABBVIE INC. $37,539.45 10/09/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158,834.54 10/09/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184248918
Principal investigator 1 ABBVIE INC. $75.00 10/02/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513089
Principal investigator 1 ABBVIE INC. $225.00 10/01/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512942
Principal investigator 1 ABBVIE INC. $97.98 09/30/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512830
Principal investigator 1 ABBVIE INC. $368.94 09/25/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512328
Principal investigator 1 ABBVIE INC. $172.98 09/24/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,591.58 09/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241702
Principal investigator 1 ABBVIE INC. $472.98 09/18/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202511432
Principal investigator 1 Novo Nordisk AS $750.00 09/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213773761
Principal investigator 1 Novo Nordisk AS $1,500.00 09/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213800790
Principal investigator 1 Novo Nordisk AS $750.00 09/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213834498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $557.25 09/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184237548
Principal investigator 1 Novo Nordisk AS $2,800.00 09/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9536-7545 No dispute reported 06/30/2026 1213787443
Principal investigator 1 ABBVIE INC. $906.68 09/11/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202510676
Principal investigator 1 ABBVIE INC. $56,168.90 09/04/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509346
Principal investigator 1 ABBVIE INC. $391.92 09/04/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509348
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,820.58 09/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,275.16 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.20 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,632.50 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $552.03 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $96.28 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $63.02 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.72 08/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230435
Principal investigator 1 ABBVIE INC. $750.00 08/21/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202505489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $557.25 08/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,965.26 08/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,197.04 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109.08 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,755.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $450.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.25 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,632.50 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.20 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.70 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22.92 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22.92 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5.49 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $377.21 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 08/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226229
Principal investigator 1 ABBVIE INC. $36,975.72 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503243
Principal investigator 1 Novo Nordisk AS $2,237.24 07/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213758184
Principal investigator 1 PFIZER INC. $2,962.00 07/18/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCEDAILY ORAL DANUGLIPRON IN ADULTS WITH OVERWEIGHT OR OBESITY No dispute reported 06/30/2026 1228762349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $557.25 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.72 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.40 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.00 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.32 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.64 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.52 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $225.00 07/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,263.33 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.12 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.20 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $557.25 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,671.75 07/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212933
Principal investigator 1 ABBVIE INC. $49,920.81 07/02/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,186.37 06/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209255
Principal investigator 1 ABBVIE INC. $6,469.00 06/18/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202492269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,943.68 06/12/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $402.87 06/12/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 06/12/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,586.25 06/12/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $742.50 06/12/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 06/12/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $964.50 06/12/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.48 06/12/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.82 06/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204241
Principal investigator 1 ABBVIE INC. $81,276.48 06/03/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $769.50 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,748.25 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.45 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,632.50 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,027.50 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.88 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.94 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $742.50 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.42 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $889.50 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $182.25 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $814.50 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $59.08 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $742.50 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $700.00 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $586.25 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $104.00 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198953
Principal investigator 1 Novo Nordisk AS $3,000.00 05/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9536-4999 No dispute reported 06/30/2026 1213726896
Principal investigator 1 Novo Nordisk AS $3,000.00 05/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9536-7545 No dispute reported 06/30/2026 1213730856
Principal investigator 1 Novo Nordisk AS $57,507.96 05/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9536-4999 No dispute reported 06/30/2026 1213784832
Principal investigator 1 Novo Nordisk AS $15,405.27 05/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9536-7545 No dispute reported 06/30/2026 1213805629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,549.26 05/22/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,001.70 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.00 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,908.00 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,336.94 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,316.18 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $160.96 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,755.00 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,496.50 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,044.20 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $512.28 05/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194777
Principal investigator 1 ABBVIE INC. $29,321.55 05/07/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,222.25 04/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,874.04 04/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184188989
Principal investigator 1 Novo Nordisk AS $650.00 04/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9536-4999 No dispute reported 06/30/2026 1213830181
Principal investigator 1 ABBVIE INC. $300.00 04/17/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202477367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,897.40 04/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.17 04/08/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181946
Principal investigator 1 ABBVIE INC. $150.00 04/07/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202474688
Principal investigator 1 ABBVIE INC. $12,870.99 04/03/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202470095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,748.25 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $156.00 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $604.35 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180624
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,121.38 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $225.00 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $497.10 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,791.45 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,791.45 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.28 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $797.10 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,748.25 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.62 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.00 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,748.25 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $454.46 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,755.00 04/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180800
Principal investigator 1 Novo Nordisk AS $450.00 03/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9536-7545 No dispute reported 06/30/2026 1213820836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,700.96 03/25/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,152.74 03/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $525.00 03/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $185.34 03/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174474
Principal investigator 1 ABBVIE INC. $150.00 03/13/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202463267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,076.37 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $261.71 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $877.50 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,832.25 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.40 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.19 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.40 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,265.00 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 03/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170816
Principal investigator 1 ABBVIE INC. $46,231.46 03/07/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202460348
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,439.31 03/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,444.45 02/25/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155444
Principal investigator 1 Novo Nordisk AS $500.00 02/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
NN9536-7545 No dispute reported 06/30/2026 1213722175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,641.00 02/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,497.50 02/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $411.29 02/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.20 02/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,072.10 02/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 02/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154324
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 02/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 02/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,279.47 02/11/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152994
Principal investigator 1 ABBVIE INC. $30,494.35 02/06/2025 Non-covered Recipient Entity
JACKSONVILLE CTR FOR CLINICAL RSRCH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,395.71 02/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,198.09 01/29/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149926
Principal investigator 1 Amgen Inc. $317,197.92 01/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246643075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,802.38 01/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,343.83 01/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,457.87 01/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,662.02 01/07/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145942